Journal of Antimicrobial Chemotherapy (1996) 38, 819-828
© 1996 The British Society for Antimicrobial Chemotherapy
other |
Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model
aDepartment of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 bNeXtar Pharmaceuticals, Inc. 650 Cliffside Dr., San Dimas, CA, USA
Received 19 May 1995; returned 11 July 1995; accepted 7 June 1996
Disseminated Mycobacterium avium complex (MAC) infection has reached epidemic proportions and is a major cause of morbidity and mortality in AIDS patients. We have developed a liposomal preparation of amikacin, VS107, which incorporates the drug in 54–65 nm diameter unilameller phospholipid vesicles and is stable at 4°C for more than 4 months. VS107 exhibits superior microbiological and pharmacological activity over the free amikacin and improves the survival of mice in the established model for MAC infection. The serum half-life of VS107 in mice was 9.1 h and a peak serum level of 730 mg/L was obtained after administering three doses of 160 mg/kg. For the therapeutic study, beige mice infected with 107 cfu M. avium complex strain 101 were randomised to be treated with placebo liposomes, buffer, free amikacin or VS107 The drugs were administered via the caudal vein thrice weekly for 1, 3, 5 or 7 weeks beginning 5 days after infection. After 51 days of treatment with VS107, the number of viable M. avium in the liver and spleen was a 100 fold lower than was achieved with conventional amikacin (P < 0.01), and more than six decimal logarithms lower than was found untreated controls (P < 0.001). VS107 was well tolerated and might be a suitable candidate for treating human MAC infections.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. E. M. de Steenwinkel, W. van Vianen, M. T. ten Kate, H. A. Verbrugh, M. A. van Agtmael, R. M. Schiffelers, and I. A. J. M. Bakker-Woudenberg Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice J. Antimicrob. Chemother., November 1, 2007; 60(5): 1064 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Banerjee Liposomes: Applications in Medicine J Biomater Appl, July 1, 2001; 16(1): 3 - 21. [Abstract] [PDF]
|
|
|
|
 |
|
 I. A. J. M. Bakker-Woudenberg, M. T. ten Kate, L. Guo, P. Working, and J. W. Mouton Improved Efficacy of Ciprofloxacin Administered in Polyethylene Glycol-Coated Liposomes for Treatment of Klebsiella pneumoniae Pneumonia in Rats Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1487 - 1492. [Abstract] [Full Text]
|
|
|
|
|
|
M. M. Gaspar, S. Neves, F. Portaels, J. Pedrosa, M. T. Silva, and M. E. M. Cruz Therapeutic Efficacy of Liposomal Rifabutin in a Mycobacterium avium Model of Infection Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2424 - 2430. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Quenelle, J. K. Staas, G. A. Winchester, E. L. W. Barrow, and W. W. Barrow Efficacy of Microencapsulated Rifampin in Mycobacterium tuberculosis-Infected Mice Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1144 - 1151. [Abstract] [Full Text]
|
|
|
|
|
|
E. L. W. Barrow, G. A. Winchester, J. K. Staas, D. C. Quenelle, and W. W. Barrow Use of Microsphere Technology for Targeted Delivery of Rifampin to Mycobacterium tuberculosis-Infected Macrophages Antimicrob. Agents Chemother., October 1, 1998; 42(10): 2682 - 2689. [Abstract] [Full Text]
|
|